MedTrace Logo

Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis

NCT02590510 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-28

No results posted yet for this study

Summary

The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.

Conditions

  • Meningeal Carcinomatosis

Interventions

DRUG

methotrexate

The quantity of methotrexate is different in the two groups.

Sponsors & Collaborators

  • Hui Bu

    lead OTHER

Principal Investigators

  • Hui · The Second Hospital of Hebei Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02590510 on ClinicalTrials.gov